SCHEMBL4454530

SCHEMBL4454530

O=CCCNCCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8312541 0.84
SCHEMBL4579266 0.83
SCHEMBL15028890 0.81 HIF1A (0.44)
SCHEMBL26741099 0.79 TSHR (0.42)
Diethanolamine SCHEMBL1836109 0.78 MEN1 (0.33)
Diethanolamine SCHEMBL23363665 0.77 TSHR (0.36)
Diethanolamine SCHEMBL5843119 0.77
Diethanolamine SCHEMBL8930798 0.77 TSHR (0.36)
Diethanolamine SCHEMBL2324 0.77
Diethanolamine SCHEMBL5307430 0.77 TSHR (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914182-B Quinazoline derivatives ASTRAZENECA AB 2011-09-07 CN disclosed
US-7632840-B2 Quinazoline compounds for the treatment of hyperproliferative disorders ASTRAZENECA AB (SE) 2009-12-15 US disclosed
EP-1713781-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2008-11-05 EP disclosed
US-20070293490-A1 Quinazoline Derivatives ASTRAZENECA AB (SE) 2007-12-20 US disclosed
CN-1914182-A Quinazoline derivatives ASTRAZENECA AB (SE) 2007-02-14 CN disclosed
EP-1713781-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2006-10-25 EP disclosed
WO-2005075439-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-08-18 WO disclosed